Cite
HARVARD Citation
Moreno, V. et al. (n.d.). 1162PCemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). Annals of oncology. p. . [Online].